Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. [electronic resource]
Producer: 20210208Description: 2192-2195 p. digitalISSN:- 1528-0020
- Adenine -- analogs & derivatives
- Agammaglobulinaemia Tyrosine Kinase -- genetics
- Aged
- Antineoplastic Agents -- therapeutic use
- Bridged Bicyclo Compounds, Heterocyclic -- therapeutic use
- Drug Resistance, Neoplasm -- genetics
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Male
- Middle Aged
- Molecular Targeted Therapy
- Mutation
- Phospholipase C gamma -- genetics
- Piperidines -- therapeutic use
- Proto-Oncogene Proteins c-bcl-2 -- genetics
- Sulfonamides -- therapeutic use
No physical items for this record
Publication Type: Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.